Parent award - medicinal chemistry support program for therapeutic development
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- HHSN271201800001I
- Awardee
-
Curia Global Inc. UEI ELCNZCS8GEA3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Task orders
- 26 $42,165,989 obligated
Award facts
- Opportunity
-
- NIHNINDS1701 Solicitation number
- Medicinal Chemistry Support Program for Therapeutic Development (MCSP) Award Notice · Posted Mar 19, 2018
- Medicinal Chemistry Support Program for Therapeutic Development (MCSP) Award Notice · Posted Jun 30, 2017
- Combined order value
-
- $43,622,406 Current, with exercised options
- $62,126,371 Potential, with all options
- Last date to order 86% complete
- IDV ceiling 61% used
- $69,645,159.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 4 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
Award details come from SAM.gov/FPDS.
About this IDV
The National Institute of Neurological Disorders and Stroke awarded a single-award indefinite-delivery contract to Curia Global Inc. (doing business as Amri) on March 16, 2018, with a ceiling value of $69,645,159.00 and an ultimate completion date of March 15, 2028. Work is performed in Albany, New York.
The contract supports the Medicinal Chemistry Support Program for Therapeutic Development, providing end-to-end pharmaceutical research and development services spanning exploratory chemistry, hit-to-lead chemistry, lead optimization chemistry, absorption/distribution/metabolism/excretion (ADME) testing, process chemistry, scale-up synthesis, good manufacturing practices (GMP) production, and stability testing across therapeutic areas including neurology, infectious diseases, substance abuse, and translational sciences. The IDIQ covers multiple performance areas, including tech transfer, storage, handling, distribution, and IT security for an existing compound repository.
All delivery orders issued under this IDIQ carry cost-plus-fixed-fee pricing except the initial task order (firm fixed price). Recent delivery orders include the Martin (Nuvonuro) program for hit-to-lead chemistry and ADME testing; Tsukamoto (Johns Hopkins University) for lead optimization chemistry; Spigelman (UCLA) for exploratory chemistry; Aldrich (University of Florida) for exploratory chemistry and ADME testing; Grace (University of Texas MD Anderson Cancer Center) for hit-to-lead chemistry; Lu (Texas A&M University) for hit-to-lead chemistry; Ganesh (Emory University) for hit-to-lead chemistry; Shamloo (Stanford University) for exploratory chemistry; Al-Ali (University of Miami) for exploratory chemistry; Trushina (National Institute of Mental Health) for Alzheimer's disease exploratory chemistry; and Florio (Anagin) for stroke-focused exploratory chemistry. These orders draw from multiple NIH institutes including the National Institute on Drug Abuse, National Institute on Aging, and National Institute of Mental Health, in addition to NINDS.
Task orders
Show all 26
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract HHSN271201800001I?
HHSN271201800001I was awarded to Curia Global Inc. by National Institute on Drug Abuse (National Institutes of Health) on March 16, 2018.
How much is contract HHSN271201800001I worth?
Orders under HHSN271201800001I have obligated $42,165,989. Their combined current value, with exercised options, is $43,622,406. Their combined potential value, with all options, is $62,126,371. HHSN271201800001I's own ceiling is $69,645,159.
How many orders have been placed under contract HHSN271201800001I?
26 orders have been placed under HHSN271201800001I, the latest on September 21, 2026.
Which agency awarded contract HHSN271201800001I?
National Institute on Drug Abuse (National Institutes of Health) awarded HHSN271201800001I, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
Who can order from contract HHSN271201800001I?
HHSN271201800001I is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract HHSN271201800001I competed?
The extent of competition for HHSN271201800001I was full and open competition. The government received 4 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV